Boston Scientific CFO Jeffrey Capello says the medical device giant is looking to capitalize on the reliability of its ICD leads, especially in light of the “challenges” faced by an ICD competitor. Boston Scientific (NYSE:BSX) is looking for ways to leverage its product pipeline in 2013, part of which may include capitalizing on some of the “challenges” facing one of their biggest rivals. Neither CEO Michael Mahoney, nor CFO Jeffrey Capello named names during a breakout session following a presentation at the J.P. Morgan Healthcare conference in San Francisco, but its likely the executives were referring to St. Jude Medical (NYSE:STJ), and its ongoing difficulties with their recalled Riata defibrillator leads.
